ESMO 2024 Trial Updates: Contact-02

Opinion
Video

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay up to date on practice-changing data in community practice.

    Subscribe Now!
    Recent Videos
    3 experts are featured in this series.
    COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
    3 experts are featured in this series.
    Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
    Clinical Impact of COCOON: Advancing Dermatologic AE Management
    Clinical Impact of COCOON: Advancing Dermatologic AE Management
    Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
    Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
    Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
    Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
    Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
    Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
    1 expert is featured in this series.
    Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
    3 experts are featured in this series.
    Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
    3 experts are featured in this series.
    Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
    Related Content
    Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

    Nadofaragene Firadenovec Shows Promise in Japanese Patients With BCG-Unresponsive NMIBC

    Jason M. Broderick
    April 22nd 2025
    Article

    The gene therapy nadofaragene firadenovec demonstrated strong clinical activity in Japanese patients with BCG-unresponsive non–muscle-invasive bladder cancer.

    Read More

    FDA Grants Approval to Durvalumab in MIBC

    FDA Grants Approval to Durvalumab in MIBC

    Jordyn Sava
    March 28th 2025
    Article

    This approval of durvalumab marks the first and only perioperative immunotherapy regimen available in muscle-invasive bladder cancer.

    Read More

    Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

    Bel-Sar Shows Promising Clinical and Immune Activity in NMIBC

    Jordyn Sava
    March 26th 2025
    Article

    Belzupacap sarotalocan showed rapid immune activation and a favorable safety profile as a treatment for non–muscle-invasive bladder cancer.

    Read More

    Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

    Blue Light Cystoscopy Associated With Lower Risk of Recurrence of NMIBC

    Jonah Feldman
    March 24th 2025
    Article

    A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who had blue light vs white light cystoscopy.

    Read More

    EAP Enhances Access to Cretostimogene Grenadenorepvec

    EAP Enhances Access to Cretostimogene Grenadenorepvec

    Hannah Clarke
    March 12th 2025
    Article

    An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.

    Read More

    Expert Explores Trials in CIS-Refractory Bladder Cancer

    Expert Explores Trials in CIS-Refractory Bladder Cancer

    Jason M. Hafron, MD, CMO
    March 12th 2025
    Article

    Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.

    Read More